GPC3-targeting IL-15-armored CAR-NK cells (Nanfang Hospital)

N/A

Report date: 2026/04/22 20:01:10

Base Information

Drug NameGPC3-targeting IL-15-armored CAR-NK cells (Nanfang Hospital)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyCell and gene therapy > Gene therapy > ElectroporationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9

Mechanisms of ActionAnti-Glypican-3Interleukin-15 receptors agonists

TargetsGlypican-3Interleukin-15 receptors

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesSouthern Hospital Of Southern Medical University

China Registration ClassN/A

Develop Information

Active CompaniesSouthern Hospital Of Southern Medical University

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A